The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

1. Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2014
This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with
comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type,
along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease
(Chronic Renal Failure) and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure) The report reviews key pipeline products
under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The
report reviews key players involved in the therapeutics development for Chronic Kidney Disease (Chronic Renal Failure) and enlists all their major and minor
projects The report summarizes all the dormant and discontinued pipeline projects A review of the Chronic Kidney Disease (Chronic Renal Failure) products
under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products
coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and
combination therapy pipeline projects Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of target, MoA, route of
administration and molecule type Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic
Renal Failure) Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline
projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics Develop and design in-licensing
and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the
therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
table Of Contents
table Of Contents 2
list Of Tables 7
list Of Figures 8
introduction 9
global Markets Direct Report Coverage 9
chronic Kidney Disease (chronic Renal Failure) Overview 10
therapeutics Development 11
pipeline Products For Chronic Kidney Disease (chronic Renal Failure) Overview 11
pipeline Products For Chronic Kidney Disease (chronic Renal Failure) Comparative Analysis 12
chronic Kidney Disease (chronic Renal Failure) Therapeutics Under Development By Companies 13
chronic Kidney Disease (chronic Renal Failure) Therapeutics Under Investigation By Universities/institutes 17
chronic Kidney Disease (chronic Renal Failure) Pipeline Products Glance 18
late Stage Products 18
clinical Stage Products 19
early Stage Products 20
chronic Kidney Disease (chronic Renal Failure) Products Under Development By Companies 21
chronic Kidney Disease (chronic Renal Failure) Products Under Investigation By Universities/institutes 23
chronic Kidney Disease (chronic Renal Failure) Companies Involved In Therapeutics Development 24
sanofi 24
astrazeneca Plc 25
eli Lilly And Company 26
quark Pharmaceuticals, Inc. 27
opko Health, Inc. 28
toray Industries, Inc. 29
evotec Ag 30
la Jolla Pharmaceutical Company 31
alexion Pharmaceuticals, Inc. 32
acceleron Pharma, Inc. 33
nippon Zoki Pharmaceutical Co., Ltd. 34
catabasis Pharmaceuticals, Inc. 35
angion Biomedica Corp. 36
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2014

2. thrasos, Inc. 37
concert Pharmaceuticals, Inc. 38
cormedix, Inc. 39
vitae Pharmaceuticals, Inc. 40
stelic Institute & Co. 41
sorbent Therapeutics, Inc. 42
vicore Pharma Ab 43
invasc Therapeutics, Inc. 44
sphaera Pharma Pvt. Ltd. 45
multi Gene Vascular Systems Ltd 46
chiasma, Inc. 47
chronic Kidney Disease (chronic Renal Failure) Therapeutics Assessment 48
assessment By Monotherapy Products 48
assessment By Combination Products 49
assessment By Target 50
assessment By Mechanism Of Action 53
assessment By Route Of Administration 56
assessment By Molecule Type 58
drug Profiles 61
beraprost Sodium La - Drug Profile 61
product Description 61
mechanism Of Action 61
r&d Progress 61
sotatercept - Drug Profile 64
product Description 64
mechanism Of Action 64
r&d Progress 64
eculizumab - Drug Profile 66
product Description 66
mechanism Of Action 66
r&d Progress 66
gcs-100 - Drug Profile 69
product Description 69
mechanism Of Action 69
r&d Progress 69
deferiprone - Drug Profile 71
product Description 71
mechanism Of Action 71
r&d Progress 71
(losartan Potassium + Alpha Lipoic Acid) - Drug Profile 73
product Description 73
mechanism Of Action 73
r&d Progress 73
tenapanor - Drug Profile 74
product Description 74
mechanism Of Action 74
r&d Progress 74
ly-3016859 - Drug Profile 76
product Description 76
mechanism Of Action 76
r&d Progress 76
enalapril Maleate - Drug Profile 77
product Description 77
mechanism Of Action 77
r&d Progress 77
sar-407899 - Drug Profile 78
product Description 78
mechanism Of Action 78
r&d Progress 78
vtp-27999 - Drug Profile 79
product Description 79
mechanism Of Action 79
r&d Progress 79
clp-1004 - Drug Profile 81
product Description 81
mechanism Of Action 81
r&d Progress 81
ctp-499 - Drug Profile 82
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2014

3. product Description 82
mechanism Of Action 82
r&d Progress 82
small Molecule For Chronic Kidney Disease - Drug Profile 84
product Description 84
mechanism Of Action 84
r&d Progress 84
small Molecule For Chronic Kidney Disease - Drug Profile 85
product Description 85
mechanism Of Action 85
r&d Progress 85
ghrelin - Drug Profile 86
product Description 86
mechanism Of Action 86
r&d Progress 86
thr-123 - Drug Profile 87
product Description 87
mechanism Of Action 87
r&d Progress 87
c-21 - Drug Profile 88
product Description 88
mechanism Of Action 88
r&d Progress 88
cat-4000 Series - Drug Profile 90
product Description 90
mechanism Of Action 90
r&d Progress 90
ang-3070 - Drug Profile 91
product Description 91
mechanism Of Action 91
r&d Progress 91
multigenegraft - Drug Profile 92
product Description 92
mechanism Of Action 92
r&d Progress 92
cxa-10 - Drug Profile 93
product Description 93
mechanism Of Action 93
r&d Progress 93
cat-4001 - Drug Profile 94
product Description 94
mechanism Of Action 94
r&d Progress 94
sphk2 Program - Drug Profile 95
product Description 95
mechanism Of Action 95
r&d Progress 95
tpx-200 - Drug Profile 96
product Description 96
mechanism Of Action 96
r&d Progress 96
nz-419 - Drug Profile 97
product Description 97
mechanism Of Action 97
r&d Progress 97
small Molecule To Inhibit Epoxide Hydrolase For Chronic Kidney Disease - Drug Profile 98
product Description 98
mechanism Of Action 98
r&d Progress 98
vida-5 - Drug Profile 99
product Description 99
mechanism Of Action 99
r&d Progress 99
sirna For Chronic Diseases - Drug Profile 101
product Description 101
mechanism Of Action 101
r&d Progress 101
stnm-310 - Drug Profile 102
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2014

4. product Description 102
mechanism Of Action 102
r&d Progress 102
ang-4011 - Drug Profile 103
product Description 103
mechanism Of Action 103
r&d Progress 103
drug For Kidney Diseases - Drug Profile 104
product Description 104
mechanism Of Action 104
r&d Progress 104
chronic Kidney Disease Program - Drug Profile 105
product Description 105
mechanism Of Action 105
r&d Progress 105
drugs To Inhibit Cyp24 For Ckd And Pre-ckd - Drug Profile 106
product Description 106
mechanism Of Action 106
r&d Progress 106
small Molecules For Chronic Kidney Disease - Drug Profile 107
product Description 107
mechanism Of Action 107
r&d Progress 107
small Molecules For Chronic Kidney Disease - Drug Profile 108
product Description 108
mechanism Of Action 108
r&d Progress 108
fluorophosphophloretin - Drug Profile 109
product Description 109
mechanism Of Action 109
r&d Progress 109
brn-1889 - Drug Profile 110
product Description 110
mechanism Of Action 110
r&d Progress 110
chronic Kidney Disease (chronic Renal Failure) Recent Pipeline Updates 111
chronic Kidney Disease (chronic Renal Failure) Dormant Projects 129
chronic Kidney Disease (chronic Renal Failure) Discontinued Products 130
chronic Kidney Disease (chronic Renal Failure) Product Development Milestones 131
featured News & Press Releases 131
mar 10, 2014: La Jolla Pharmaceutical Company Reports Positive, Top-line Results From Phase 2 Clinical Trial Of Gcs-100 In Chronic Kidney Disease 131
feb 21, 2014: La Jolla Pharmaceutical Company Announces Final Dosing In Phase 2 Clinical Trial Of Gcs-100 In Chronic Kidney Disease 132
jan 15, 2014: La Jolla Pharmaceutical Company Announces The Start Of A Phase 2 Extension Study Of Gcs-100 In Chronic Kidney Disease 132
dec 16, 2013: La Jolla Pharmaceutical Company Announces Complete Enrollment Of Phase 2 Clinical Trial Of Gcs-100 In Chronic Kidney Disease 133
nov 20, 2013: Kyowa Hakko Kirin Announces The Development Status Of Bardoxolone Methyl (rta 402) In Patients With Chronic Kidney Disease And Type 2
Diabetes In Japan 134
nov 15, 2013: Opko Completes Patient Recruitment In First Phase 3 Trial Of Rayaldy 134
sep 24, 2013: Phase 3 Data On Heplisav In Adults Aged 40-70 And Patients With Chronic Kidney Disease Published In Vaccine 135
sep 03, 2013: Rockwell Medical To Discuss Top-line Results From Final Sfp Phase 3 Efficacy Study Cruise-2 135
sep 02, 2013: New Protocols To Accelerate Iv Erepoxen Trials In India 136
aug 06, 2013: La Jolla Pharmaceutical Company Abstract Accepted For The American Society Of Nephrology Kidney Week 2013 136
appendix 137
methodology 137
coverage 137
secondary Research 137
primary Research 137
expert Panel Validation 137
contact Us 138
disclaimer 138
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2014

5. M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2014